BGI, Merck Agree to Explore Areas of Interest in Next-gen Sequencing

The statement of intent signed today is the first step toward bringing together Merck's expertise in pharmaceutical development "with the powerful sequencing and bioinformatics capabilities of BGI," a Merck official said.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.